Why the study?
Thrombosis remains a major cause of morbidity and mortality, necessitating advances in antithrombotic therapy to reduce disease burden.
Does low-dose rivaroxaban plus aspirin or factor XI inhibition improve outcomes and safety in patients with coronary or peripheral artery disease?
Does low-dose rivaroxaban plus aspirin or factor XI inhibition improve outcomes and safety in patients with coronary or peripheral artery disease?
This review highlights the efficacy of low-dose rivaroxaban plus aspirin in CAD/PAD and the potential of factor XI inhibitors as safer anticoagulants.
Supports dual pathway inhibition in CAD/PAD; leaves open bleeding mitigation and optimal patient selection.
Thrombosis remains a major cause of morbidity and mortality. Consequently, advances in antithrombotic therapy are needed to reduce the disease burden. This article focuses on 2 such advances. First, the prevention of atherothrombosis in patients with coronary or peripheral artery disease, which has been enhanced by the finding that the combination of low-dose rivaroxaban plus aspirin is superior to aspirin alone for prevention of recurrent ischemic events. However, this benefit comes at the cost of increased bleeding albeit not fatal bleeding. To overcome this problem, the second advance is the identification of factor XI as a target for new anticoagulants that are potentially safer than those currently available.
No takes yet. Share an insight, caveat, or question.
Weitz et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: